Last reviewed 2026-05-14 · How we verify

GSK4382276A Dose level 10

GlaxoSmithKline · Phase 1 active Biologic

GSK4382276A Dose level 10 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development. Also known as: Flu mRNA.

At a glance

Generic name	GSK4382276A Dose level 10
Also known as	Flu mRNA
Sponsor	GlaxoSmithKline
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK4382276A Dose level 10 CI brief — competitive landscape report
GSK4382276A Dose level 10 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about GSK4382276A Dose level 10

What is GSK4382276A Dose level 10?

GSK4382276A Dose level 10 is a Biologic drug developed by GlaxoSmithKline.

Who makes GSK4382276A Dose level 10?

GSK4382276A Dose level 10 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is GSK4382276A Dose level 10 also known as anything else?

GSK4382276A Dose level 10 is also known as Flu mRNA.

What development phase is GSK4382276A Dose level 10 in?

GSK4382276A Dose level 10 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Also known as: Flu mRNA
Compare: GSK4382276A Dose level 10 vs similar drugs
Pricing: GSK4382276A Dose level 10 cost, discount & access